TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04861649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)
Study: NCT06006182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape Powder
Description: Freeze-dried grape powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grape Powder
Description: Freeze-dried grape powder
Study: NCT05707273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo T-cell leukapheresis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05698901

Intervention type: DRUG
Intervention: Agalsidase beta
Description: The treatment is following local reimbursement criteria and judge by physician
Study: NCT05079672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,9% Saline
Description: Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.
Study: NCT06542419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Cooling
Description: Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, while listening to calming natural sounds, during which they will wear an Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability. This brain cooling treatment will occur on 7 consecutive days.
Study: NCT05709626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aspirin (Prasugurel monotherapy)
Description: 12-month prasugrel monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month DAPT
Description: 12-month dual antiplatelet therapy with prasugrel and aspirin
Study: NCT05380882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2930 injection
Description: TQB2930 is an anti-HER2 bispecific antibody.
Study: NCT06536699

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - hypofractionated
Description: Hypofractionated Radiotherapy of 55 Gy in 20 fractions in definitive setting and 52.5 Gy in 20 fractions in adjuvant setting. Total duration - 4 Weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy - Conventional
Description: Conventional Radiotherapy of 66 Gy in 30 fractions in definitive setting and 60 Gy in 30 fractions in adjuvant setting. Total duration - 6 Weeks
Study: NCT04759716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Literacy-based Weight Control Intervention
Description: intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
Study: NCT06087302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: child-Parent Relationship Therapy (CPRT)
Description: The Child Parent Relationship Therapy (CPRT) is an evidence-based intervention program that trains parents/caretakers to help their children with social, emotional, attachment, and behavioral difficulties
Study: NCT04766593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncological functional reeducation program
Description: It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oncological functional reeducation program
Description: It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living.
Study: NCT06059287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: Henagliflozin 10mg qd po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000mg bid po
Study: NCT06721104

Intervention type: OTHER
Intervention: Cervical Posture Assessment:
Description: Cervical posture will be evaluated using the Android-based PostureScreen Mobile application (version 8.5, developed by Posture Co. Inc., USA). This application assesses the static posture of individuals. After determining reference points, the application draws reference lines and records postural deviations. At least two photos of each participant will be taken for the assessment. Participants should not wear clothing items that cover the neck (e.g., scarves, shawls).~While the primary focus of the application is to assess postural deviations, it also includes a dental evaluation feature. The validity and reliability of the application have been established in previous studies. In addition to using the application, the posture of individuals will also be evaluated through observational analysis, and the findings will be documented.

Intervention type: OTHER
Intervention: Temporomandibular Joint (TMJ) Assessment
Description: The TMJ will be evaluated using the Helkimo Clinical Craniomandibular Index. This index consists of five subcategories: pain during muscle palpation, pain during TMJ palpation, pain during mandibular functions, TMJ functions (sounds, gliding during maximum opening, dislocation and/or locking), and the mandibular range of motion. Each subcategory is scored as 0, 1, or 5, resulting in a total score ranging from 0 to 25.~As this index is based on performance measurements, there is no Turkish validity and reliability study for it. However, a prevalence study using this index was conducted in Turkey by Üner et al. to evaluate its applicability within the Turkish population.

Intervention type: OTHER
Intervention: Temporomandibular Joint (TMJ) Assessment
Description: The TMJ will be evaluated using the Helkimo Clinical Craniomandibular Index. This index consists of five subcategories: pain during muscle palpation, pain during TMJ palpation, pain during mandibular functions, TMJ functions (sounds, gliding during maximum opening, dislocation and/or locking), and the mandibular range of motion. Each subcategory is scored as 0, 1, or 5, resulting in a total score ranging from 0 to 25.~As this index is based on performance measurements, there is no Turkish validity and reliability study for it. However, a prevalence study using this index was conducted in Turkey by Üner et al. to evaluate its applicability within the Turkish population.
Study: NCT06721195

Intervention type: DRUG
Intervention: Remimazolam for Gastrointestinal Endoscopy Sedation
Description: This intervention involves the use of remimazolam, a short-acting benzodiazepine, for sedation during gastrointestinal endoscopy procedures (gastroscopy, colonoscopy, or both). Remimazolam is administered intravenously at an initial dose of 0.2-0.3 mg/kg, followed by additional doses of 2.5 mg as needed to maintain adequate sedation (MOAA/S score ≤ 2).~Unlike other benzodiazepines, remimazolam is rapidly metabolized by plasma esterases, resulting in a quick onset and recovery with minimal respiratory and cardiovascular depression. The study specifically evaluates the euphoria-inducing potential of remimazolam, using the ARCI-MBG scale pre- and post-procedure to assess its effect on patient comfort and satisfaction.
Study: NCT06720506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: Fentanyl will be given intrathecal with dose 10-20ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine will given IV as shot in Dose 1mg /kg
Study: NCT06721533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere
Study: NCT06286683

Intervention type: DEVICE
Intervention: lung ultrasound
Description: Used to diagnose and monitor pulmonary aeration in the context of prolonged decubitus disorders (atelectasis) via the lung ultrasound score (LUS).

Intervention type: DEVICE
Intervention: Transcranial Doppler
Description: Non-invasive, bedside method of measuring cerebral blood flow.

Intervention type: DEVICE
Intervention: near-infrared spectroscopy (NIRS)
Description: Non-invasive, bedside method of cerebral oximetry that requires no advanced expertise.

Intervention type: DEVICE
Intervention: clinical examination
Description: clinical examination
Study: NCT06360172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing, or MI, is a collaborative, person-centered counseling technique to uncover and enhance a person\&#39;s motivation for behavior change
Study: NCT06205771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H2S content
Description: H2S content
Study: NCT04316338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Description: Non-invasive brain stimulation technique
Study: NCT06509932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jefcare Sterile Medical Sheets
Description: Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.

Intervention type: DEVICE
Group type: OTHER
Intervention: MoliCare Premium Bed Mats
Description: Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
Study: NCT06444919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 179 Mg Cutaneous Patch
Description: patch application for 30 minutes on the painful fingers.
Study: NCT06721533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere
Study: NCT05975216

Intervention type: OTHER
Intervention: Contact the patient
Description: Phone call, email or letter to contact the patient to relink them.
Study: NCT05303480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlormethine
Description: Chlormethine gel 0.016%
Study: NCT06721533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere
Study: NCT05982522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: orally taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 125 mg/m2 D1, 8 Q3W, Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m2 D1, 8 Q3W, Intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200mg Q3W, Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg Q3W, Intravenously
Study: NCT05298176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib, Osimertinib, Carboplatin and Pemetrexed
Description: This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
Study: NCT06721533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere
Study: NCT06721871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crofelemer Powder for Oral Solution
Description: Crofelemer Powder for Oral Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crofelemer Powder for Oral Solution
Description: Crofelemer Powder for Oral Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crofelemer Powder for Oral Solution
Description: Crofelemer Powder for Oral Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crofelemer Powder for Oral Solution
Description: Crofelemer Powder for Oral Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crofelemer Powder for Oral Solution
Description: Crofelemer Powder for Oral Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crofelemer Powder for Oral Solution
Description: Crofelemer Powder for Oral Solution
Study: NCT06444919

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Capsaicine low dose 0.04 %
Description: patch application for 30 minutes on the painful fingers. the low-dose patch has a similar appearance to the active patch. It allows you to keep the blind, because it also causes reactions at the capsaicin application site (erythema, burning).
Study: NCT05481632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoangel assisted the process of colonoscopy
Description: Endoangel assisted doctors to detect polyps

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Colonoscopy was performed without endoangel assistance
Description: Polyps were detected without ENDOANGEL assistance
Study: NCT06371924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Machine Perfusion
Description: The quality of DCD organs can be improved by replacing the icebox (static cold storage or SCS), which remains the main approach to preserve the livers after having been retrieved, by strategies that perfuse the livers in a machine (machine perfusion or MP). There are currently 3 MP strategies employed in the clinic: normothermic regional perfusion (NRP) is used in the donors by perfusing the liver with the donor's blood at 37 degrees Celsius, and normothermic (NMP) or hypothermic (HOPE) perfusion are used in the procured livers out of the body (using warm or cold perfusion fluids, respectively). To date, no controlled objective comparisons of these different MP strategies have been undertaken and the doctors do not have a good understanding of their mechanisms of action.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Machine Perfusion
Description: The quality of DCD organs can be improved by replacing the icebox (static cold storage or SCS), which remains the main approach to preserve the livers after having been retrieved, by strategies that perfuse the livers in a machine (machine perfusion or MP). There are currently 3 MP strategies employed in the clinic: normothermic regional perfusion (NRP) is used in the donors by perfusing the liver with the donor's blood at 37 degrees Celsius, and normothermic (NMP) or hypothermic (HOPE) perfusion are used in the procured livers out of the body (using warm or cold perfusion fluids, respectively). To date, no controlled objective comparisons of these different MP strategies have been undertaken and the doctors do not have a good understanding of their mechanisms of action.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Machine Perfusion
Description: The quality of DCD organs can be improved by replacing the icebox (static cold storage or SCS), which remains the main approach to preserve the livers after having been retrieved, by strategies that perfuse the livers in a machine (machine perfusion or MP). There are currently 3 MP strategies employed in the clinic: normothermic regional perfusion (NRP) is used in the donors by perfusing the liver with the donor's blood at 37 degrees Celsius, and normothermic (NMP) or hypothermic (HOPE) perfusion are used in the procured livers out of the body (using warm or cold perfusion fluids, respectively). To date, no controlled objective comparisons of these different MP strategies have been undertaken and the doctors do not have a good understanding of their mechanisms of action.
Study: NCT06021405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tape stripping
Description: a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema
Study: NCT06521996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Cycle 1: d8, 1 mg; d15, 2 mg~Cycle 2 and beyond: 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Description: Cyclophosphamide will be administered at a dose of 750 mg/ m2 IV on Day 1 of Cycle 1-6, every 21 days.~Doxorubicin will be administered at a dose of 50 mg/m2 IV on Day 1 of Cycle 1-6, during induction treatment.~Vincristine will be administered at a dose of 1.4 mg/m2 (maximum 2 mg) IV infusion in 50 ml sodium chloride 0.9% over 10 minutes on Day 1 of Cycle 1-6, every 21 days.~Methylprednisolone will be administered at fixed dose of dose 80 mg IV on Day 1 of Cycle 1-6, every 21 days.~Prednisone will be administered at a dose of 60 mg/m2 orally on Days 2-5 of Cycle 1-6, every 21 days.
Study: NCT04918017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment based on subtypes: Esomeprazole or Itopride
Description: Esomeprazole 40mg OD for EPS and Itopride 50mg TDS for PDS~In overlapped EPS/ PDS: treat with Itopride 50mg TDS first and then add Esomeprazole 40mg OD (if partially responded- assessed at week 4) or treat with Itopride 50mg TDS first and then change to Esomeprazole 40mg OD (if not responded- assessed at week 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment based on subtypes: Esomeprazole or Itopride
Description: Esomeprazole 40mg OD for EPS and Itopride 50mg TDS for PDS~In overlapped EPS/ PDS: treat with Itopride 50mg TDS first and then add Esomeprazole 40mg OD (if partially responded- assessed at week 4) or treat with Itopride 50mg TDS first and then change to Esomeprazole 40mg OD (if not responded- assessed at week 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment based on subtypes: Esomeprazole or Itopride
Description: Esomeprazole 40mg OD for EPS and Itopride 50mg TDS for PDS~In overlapped EPS/ PDS: treat with Itopride 50mg TDS first and then add Esomeprazole 40mg OD (if partially responded- assessed at week 4) or treat with Itopride 50mg TDS first and then change to Esomeprazole 40mg OD (if not responded- assessed at week 4)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with proton pump inhibitor regardless of subtype: Esomeprazole
Description: Esomeprazole 40mg OD
Study: NCT05715788

Intervention type: DRUG
Intervention: Nitric oxide
Description: Nitric oxide inhalation at 20 ppm

Intervention type: BEHAVIORAL
Intervention: prone positioning
Description: vatilation in prone position

Intervention type: BEHAVIORAL
Intervention: prone positioning
Description: vatilation in prone position
Study: NCT06332365

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acetonide triamcinolone 0.2% +hyaluronicacid 1%
Description: topical application cream form twice a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticoid Acetonide triamcinolone 0.2%
Description: topical application cream form twice a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid 1%
Description: topical application cream form twice a day for 4 weeks
Study: NCT04664283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography
Description: DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography
Description: DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
Study: NCT06454903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT to RECOVER
Description: During Phase 3 (Stage 1b RCT), the treatment condition will employ ACT to RECOVER. ACT to RECOVER will be a smartphone app designed to act as a flexible, semi-structured, user-friendly adjunct to standard medication treatment for opioid use disorder. Content will include components appropriate for either self-management and/or use with providers. ACT to RECOVER will be designed to have major ACT-focused modules completable within 1 month.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Smartphone-based Symptom-Monitoring
Description: During Phase 3 (Stage 1b RCT), the control condition will employ a smartphone-based symptom monitoring program in an effort to provide a balanced alternative to the treatment condition with respect to attention, time using a mobile application, and nonspecific intervention effects. This condition will not, however, include any content or components from the Prototype Digital Intervention hypothesized to produce active clinical effects.
Study: NCT05980351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The children will receive exercise program(stretching exercise,range of motion exercise and isometric exercise)
Study: NCT05526274

Intervention type: DIAGNOSTIC_TEST
Intervention: Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)
Description: VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
Study: NCT06537245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage was applied in the both quads during 5 or 10 minutes, with differents pressures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage was applied in the both quads during 5 or 10 minutes, with differents pressures.